340B Drug Program Fuels Hospital Profits Amid Scrutiny Over Charity Care Shortfalls

The 340B Drug Pricing Program, established in 1992 to support safety-net providers, has expanded dramatically into a $244 billion initiative, generating substantial revenues for participating hospitals while raising questions about its alignment with original intent. A recent Pioneer Institute and CancerCare analysis of nearly 4,000 hospitals found that 340B participants spent just 2.16% of operating expenses on charity care, compared to 2.82% at non-participating hospitals. The gap widened for care to uninsured patients (1.60% vs. 2.26%).

Berkeley Research Group (BRG), in a PhRMA-funded report, estimated that patients and payers spent $244.3 billion on 340B-purchased drugs in 2025, with covered entities acquiring them for $102.1 billion and realizing a $142.2 billion margin—nearly 60% retained as profit by hospitals, clinics, and partners. Sales grew 152% from 2020 to 2025, far outpacing overall U.S. drug sales growth. The program now encompasses over 1,150 hospitals and tens of thousands of contract pharmacies and off-site entities.

Critics, including the Pioneer Institute, highlight the lack of federal requirements for how profits are spent, noting that 340B hospitals serve more Medicaid patients yet provide proportionally less charity care. The American Hospital Association counters that growth stems from high drug prices set by manufacturers and expansions under the Affordable Care Act to reach underserved populations. Reforms are under discussion as policymakers examine accountability gaps.

This dynamic underscores tensions between financial incentives in healthcare and expectations for community benefit from tax-exempt nonprofits, with implications for patient access, trust in safety-net systems, and broader drug pricing policies.